Sclerosing peritonitis practolol

Practolol (Figure 8.13) was the prototype cardioselective p-adrenoceptor blocking agent. Selectivity was achieved by substitution in the para position with an acetyl anilino function. The similarity of this drug with those outlined above is obvious. Practolol caused severe skin and eye lesions in some patients which led to its withdrawal from the market [6]. These lesions manifested as a rash, hyperkeratosis, scarring, even perforation of the cornea and development of a fibrovascular mass in the conjunctiva, and sclerosing peritonitis. Some evidence is available that the drug is oxidatively metabolized to a reactive product that binds irreversibly to tissue pro-... 

Eye damage and sclerosing peritonitis with Practolol and perforated intestines with nonsteroid anti-inflammatory drugs such as indomethacin and benzoxaprofen. 

Eltringham WK, Espiner HJ, Windsor CW, Griffiths DA, Davies JD, Baddeley H, Read AE, Blunt RJ. Sclerosing peritonitis due to practolol a report on 9 cases and their surgical management. Br J Surg 1977 64(4) 229-35. 

The average length of treatment with practolol prior to the development of the first symptom of sclerosing peritonitis was about 34 months (Nicholls 1978). A disturbing feature, however, and one which eventually led to withdrawal of the drug, was that the symptoms had been reported up to 18 months after cessation of treatment (Allan and Cade 1975 Halley and Goodman 1975). About 50 patients with this particular feature of the syndrome are known to the CSM, either in conjunction with other aspects of the syndrome, or as the main one. 

---